SP acquires Spain based global provider of complete sterile filling lines
Company's strategic move reflects its expectation of short-run aseptic liquid filling to continue to drive pharmaceutical growth.
SP Industries has acquired the assets of privately held i-Dositecno. Located in Mataro, Spain, i-Dositecno is a global provider of complete sterile filling lines for pharmaceutical, cosmetic and ophthalmic applications.
“i-Dositecno has a well-earned reputation for producing high quality, fill-finish equipment complemented by strong software engineering capabilities and innovative servicing and support,” stated SP CEO Brian Larkin.
“At SP we are continually focused on bringing value to our customer relationships and i-Dositecno’s current portfolio, engineering expertise and broad capabilities in liquid filling particularly for syringes and other cartridges in addition to vials, are a very strategic complement to our Hull and VirTis freeze dryers and PennTech aseptic vial processing lines.”
Larkin continued: “As biological drug development and treatment protocols have become more specialized, we expect short-run aseptic liquid filling to continue to drive pharmaceutical growth. With the addition of i-Dositecno to our SP brand, we now join a very select group of manufacturers with the capability to provide full lines. And, while SP has traditionally had a stronger equipment footprint in the US, i-Dositecno’s efforts and success have primarily been within Europe and Asia. These relationships, as well as the addition of a Spain location to our current UK manufacturing within Europe provide significant opportunity to better serve the worldwide market. Key manufacturing, engineering, sales and service personnel from i-Dositecno have joined the SP team to assure continuity in operations and service. Oriol Casoliva, founder and past CEO of i-Dositecno will join SP’s Executive Leadership Team and we look forward to benefiting from his vision and depth of knowledge in maximizing i-Dositecno and SP’s performance within the aseptic pharmaceutical manufacturing space.“
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance